Small Molecules in Development for the Treatment of Spinal Muscular Atrophy

Alyssa N. Calder, Elliot Androphy, Kevin J. Hodgetts

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease resulting from pathologically low levels of survival motor neuron (SMN) protein. The majority of mRNA from the SMN2 allele undergoes alternative splicing and excludes critical codons, causing an SMN protein deficiency. While there is currently no FDA-approved treatment for SMA, early therapeutic efforts have focused on testing repurposed drugs such as phenylbutyrate (2), valproic acid (3), riluzole (6), hydroxyurea (7), and albuterol (9), none of which has demonstrated clinical effectiveness. More recently, clinical trials have focused on novel small-molecule compounds identified from high-throughput screening and medicinal chemistry optimization such as olesoxime (11), CK-2127107, RG7800, LMI070, and RG3039 (17). In this paper, we review both repurposed drugs and small-molecule compounds discovered following medicinal chemistry optimization for the potential treatment of SMA.

Original languageEnglish (US)
Pages (from-to)10067-10083
Number of pages17
JournalJournal of Medicinal Chemistry
Volume59
Issue number22
DOIs
StatePublished - Nov 23 2016

Fingerprint

Spinal Muscular Atrophy
Drug Repositioning
Pharmaceutical Chemistry
Motor Neurons
Phenylbutyrates
Riluzole
Protein Deficiency
Hydroxyurea
Albuterol
Alternative Splicing
Valproic Acid
Codon
Neurodegenerative Diseases
Alleles
Clinical Trials
Messenger RNA
Proteins
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Small Molecules in Development for the Treatment of Spinal Muscular Atrophy. / Calder, Alyssa N.; Androphy, Elliot; Hodgetts, Kevin J.

In: Journal of Medicinal Chemistry, Vol. 59, No. 22, 23.11.2016, p. 10067-10083.

Research output: Contribution to journalReview article

Calder, Alyssa N. ; Androphy, Elliot ; Hodgetts, Kevin J. / Small Molecules in Development for the Treatment of Spinal Muscular Atrophy. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 22. pp. 10067-10083.
@article{9c30ebcba1734d788d90589793159708,
title = "Small Molecules in Development for the Treatment of Spinal Muscular Atrophy",
abstract = "Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease resulting from pathologically low levels of survival motor neuron (SMN) protein. The majority of mRNA from the SMN2 allele undergoes alternative splicing and excludes critical codons, causing an SMN protein deficiency. While there is currently no FDA-approved treatment for SMA, early therapeutic efforts have focused on testing repurposed drugs such as phenylbutyrate (2), valproic acid (3), riluzole (6), hydroxyurea (7), and albuterol (9), none of which has demonstrated clinical effectiveness. More recently, clinical trials have focused on novel small-molecule compounds identified from high-throughput screening and medicinal chemistry optimization such as olesoxime (11), CK-2127107, RG7800, LMI070, and RG3039 (17). In this paper, we review both repurposed drugs and small-molecule compounds discovered following medicinal chemistry optimization for the potential treatment of SMA.",
author = "Calder, {Alyssa N.} and Elliot Androphy and Hodgetts, {Kevin J.}",
year = "2016",
month = "11",
day = "23",
doi = "10.1021/acs.jmedchem.6b00670",
language = "English (US)",
volume = "59",
pages = "10067--10083",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "22",

}

TY - JOUR

T1 - Small Molecules in Development for the Treatment of Spinal Muscular Atrophy

AU - Calder, Alyssa N.

AU - Androphy, Elliot

AU - Hodgetts, Kevin J.

PY - 2016/11/23

Y1 - 2016/11/23

N2 - Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease resulting from pathologically low levels of survival motor neuron (SMN) protein. The majority of mRNA from the SMN2 allele undergoes alternative splicing and excludes critical codons, causing an SMN protein deficiency. While there is currently no FDA-approved treatment for SMA, early therapeutic efforts have focused on testing repurposed drugs such as phenylbutyrate (2), valproic acid (3), riluzole (6), hydroxyurea (7), and albuterol (9), none of which has demonstrated clinical effectiveness. More recently, clinical trials have focused on novel small-molecule compounds identified from high-throughput screening and medicinal chemistry optimization such as olesoxime (11), CK-2127107, RG7800, LMI070, and RG3039 (17). In this paper, we review both repurposed drugs and small-molecule compounds discovered following medicinal chemistry optimization for the potential treatment of SMA.

AB - Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease resulting from pathologically low levels of survival motor neuron (SMN) protein. The majority of mRNA from the SMN2 allele undergoes alternative splicing and excludes critical codons, causing an SMN protein deficiency. While there is currently no FDA-approved treatment for SMA, early therapeutic efforts have focused on testing repurposed drugs such as phenylbutyrate (2), valproic acid (3), riluzole (6), hydroxyurea (7), and albuterol (9), none of which has demonstrated clinical effectiveness. More recently, clinical trials have focused on novel small-molecule compounds identified from high-throughput screening and medicinal chemistry optimization such as olesoxime (11), CK-2127107, RG7800, LMI070, and RG3039 (17). In this paper, we review both repurposed drugs and small-molecule compounds discovered following medicinal chemistry optimization for the potential treatment of SMA.

UR - http://www.scopus.com/inward/record.url?scp=84999122273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999122273&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b00670

DO - 10.1021/acs.jmedchem.6b00670

M3 - Review article

VL - 59

SP - 10067

EP - 10083

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 22

ER -